Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51254 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3TDP1MEN1 | |
| SCHEMBL2186411 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3TDP1MEN1 | |
| Methane SCHEMBL28820455 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TDP1MEN1 | |
| Dimethylamine SCHEMBL28875130 | 0.91 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3TDP1MEN1 | |
| SCHEMBL6664494 | 0.88 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3TDP1MEN1 | |
| SCHEMBL170098 | 0.88 | TDP1 (0.53) | SLC6A2SLC6A4SLC6A3TDP1MEN1 | |
| SCHEMBL131333 | 0.87 | TDP1 (0.38) | SLC6A2SLC6A4SLC6A3TDP1MEN1 | |
| SCHEMBL7765145 | 0.87 | MGLL (0.48) | TDP1MEN1KMT2ATAAR1 | |
| SCHEMBL30300699 | 0.87 | MGLL (0.48) | TDP1MEN1KMT2ATAAR1 | |
| SCHEMBL1957441 | 0.85 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110564755-B | Method for preparing (S) -3-phenyl-1, 2-epoxypropane and derivatives thereof by using biological enzyme catalysis | 河南农业大学 | 2021-01-12 | — | — | CN | claimed |
| CN-110564755-A | Method for preparing (S) -3-phenyl-1, 2-epoxypropane and derivatives thereof by using biological enzyme catalysis | 河南农业大学 | 2019-12-13 | — | — | CN | claimed |
| CN-110564755-B | Method for preparing (S) -3-phenyl-1, 2-epoxypropane and derivatives thereof by using biological enzyme catalysis | 河南农业大学 | 2021-01-12 | — | — | CN | disclosed |
| CN-110564755-B | Method for preparing (S) -3-phenyl-1, 2-epoxypropane and derivatives thereof by using biological enzyme catalysis | 河南农业大学 | 2021-01-12 | — | — | CN | disclosed |
| CN-110564755-B | Method for preparing (S) -3-phenyl-1, 2-epoxypropane and derivatives thereof by using biological enzyme catalysis | 河南农业大学 | 2021-01-12 | — | — | CN | disclosed |
| CN-110564755-A | Method for preparing (S) -3-phenyl-1, 2-epoxypropane and derivatives thereof by using biological enzyme catalysis | 河南农业大学 | 2019-12-13 | — | — | CN | disclosed |
| CN-110564755-A | Method for preparing (S) -3-phenyl-1, 2-epoxypropane and derivatives thereof by using biological enzyme catalysis | 河南农业大学 | 2019-12-13 | — | — | CN | disclosed |
| CN-110564755-A | Method for preparing (S) -3-phenyl-1, 2-epoxypropane and derivatives thereof by using biological enzyme catalysis | 河南农业大学 | 2019-12-13 | — | — | CN | disclosed |
| US-20190010129-A1 | Amide derivatives as lysophosphatidic acid receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2019-01-10 | — | — | US | disclosed |
| US-10100018-B2 | Amide derivatives as lysophosphatidic acid receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-20050222464-A1 | Preparation of P-chirogenic phospholanes and their use in asymmetric synthesis | HOGE GARRETT S II | 2005-10-06 | — | — | US | disclosed |
| EP-1341799-B1 | P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES | WARNER LAMBERT CO (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040215027-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | HOGE GARRETT STEWART | 2004-10-28 | — | — | US | disclosed |
| US-6750171-B2 | IMPROVE ENANTIOSELECTIVITY IN ASYMMETRIC REACTIONS | WARNER-LAMBERT COMPANY LLC | 2004-06-15 | — | — | US | disclosed |
| US-20030236433-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | HOGE GARRETT STEWART (US) | 2003-12-25 | — | — | US | disclosed |
| EP-1341799-A1 | P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES | Warner-Lambert Company LLC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6605745-B2 | Locates chirality closer to the metal center than known metal phospholane complexes; provide high enantiomeric excesses of formed compounds | HOGE II GARRETT STEWART (US) | 2003-08-12 | — | — | US | disclosed |
| US-20020087017-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | HOGE GARRETT STEWART (US) | 2002-07-04 | — | — | US | disclosed |
| WO-2002048161-A1 | P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040215027-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | PHOSPHO1, BPGM, PHPT1 | SLC6A2 2995/4885SLC6A4 2097/4885SLC6A3 1725/4885 |
| US-10100018-B2 | Amide derivatives as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR3 | SLC6A2 3198/4885SLC6A4 3586/4885SLC6A3 3701/4885 |
| US-20190010129-A1 | Amide derivatives as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR3 | SLC6A2 3369/4885SLC6A4 3681/4885SLC6A3 3965/4885 |
| US-20050222464-A1 | Preparation of P-chirogenic phospholanes and their use in asymmetric synthesis | PYGB, PNKP, GAP43 | SLC6A2 2425/4885SLC6A4 2084/4885SLC6A3 2650/4885 |
| US-20030236433-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | PHOSPHO1, BPGM, PHPT1 | SLC6A2 2995/4885SLC6A4 2097/4885SLC6A3 1725/4885 |
| US-20020087017-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | PHOSPHO1, BPGM, PHPT1 | SLC6A2 2995/4885SLC6A4 2097/4885SLC6A3 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.